Jump to content

Kenneth L. Davis

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Tom.Bot (talk | contribs) at 01:10, 15 December 2020 (Task 6: +{{Authority control}} (11 IDs from Wikidata), WP:GenFixes on). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Kenneth L. Davis, MD
NationalityAmerican
EducationMount Sinai School of Medicine, Stanford University School of Medicine, Stanford University Hospital
Occupation(s)President and chief executive officer of the Mount Sinai Health System
Known forPsychiatry
Medical career
FieldPsychiatry, Alzheimer's Disease, Schizophrenia
InstitutionsMount Sinai Health System
ResearchPsychiatry, Alzheimer's Disease, Schizophrenia
WebsiteKenneth L. Davis, MD

Kenneth L. Davis is president and chief executive officer of the Mount Sinai Health System in New York City, an American author and medical researcher who developed the Alzheimer's Disease Assessment Scale, the most widely used tool to test the efficacy of treatments for Alzheimer's Disease designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic to persons with Alzheimer's disease.[1][2]

Biography

Davis graduated magna cum laude from Yale College in 1969 and later was the valedictorian of Mount Sinai School of Medicine's second graduating class in 1973 with his M.D., where he received the Harold Elster Memorial Award for highest academic achievement.[3] Supplementary graduate medical education was later completed at Stanford University.

In 1979, Davis was made chief of psychiatry at Bronx Veteran's Affairs Medical Center, where he became the first director of its Schizophrenia Biological Research Center. From 1987 until 2003, he was chairman of psychiatry at Mount Sinai School of Medicine.

In 2003, Davis was appointed dean of Mount Sinai School of Medicine and held that position until 2007, when he was succeeded by Dennis S. Charney, M.D. Davis was also appointed as the president and CEO of Mount Sinai Medical Center in 2003 – positions he holds today. In 2015, Davis had gross compensation from the Icahn School of Medicine at Mount Sinai of $4,147,755. He is the director of the Mount Sinai Silvio Conte Neuroscience Center, trustee of the New York Academy of Medicine, trustee of the Aspen Institute,[4][5] and chair of the New York Academy of Medicine Deans Council. In addition, he has served as chairman of the board of governors for the Greater New York Hospital Association.

In September 2013, when Mount Sinai Medical Center merged with Continuum Health Partners, Davis became the president and CEO of the Mount Sinai Health System. In 2017, his annual salary was $12 million.[6]

Davis has weighed in on the intersection of health and public policy, arguing that the National Institutes of Health should receive more funds to fight disease and calling drug prices 'outrageous' and a fair trade issue.[7][8]

Alzheimer's research

Davis participated in breakthrough proof-of-concept studies and clinical trials of cholinesterase inhibitors. These trials (the first multicenter ones for cholinesterase inhibitors) established efficacy and ultimately led the first four of the five FDA-approved compounds for treating the symptoms of Alzheimer's: tacrine, rivastigmine, galantamine, donepezil and memantine[9]

In 1978, Davis, together with Richard Mohs, conducted the first well-controlled study of a drug that was shown able to improve the storage and retrieval functions of long-term memory in humans.[10]

In 1987, Davis participated in the first study providing strong evidence that Alzheimer's risk is inherited.[11]

While at Mount Sinai Hospital, Davis and his associates have been at the forefront in the delineation of the role of amyloid in Alzheimer's disease,[10] and were among the first to report the cloning and chromosomal location of the amyloid precursor protein, regarded as one of the most important discoveries in Alzheimer's research in the previous 15 years.[12]

Schizophrenia research

Davis's work on schizophrenia has shown that oligodendroglia cells and myelin play roles in the disease's pathophysiology[13] and that dopamine – long thought to be merely hyperactive in a schizophrenic brain – is actually hypoactive in different regions.[14]

His paper, "Dopamine in schizophrenia—a review and reconceptualization" (American Journal of Psychiatry, 148-11: 1474–86, November 1991) is the third most-cited paper on schizophrenia research in its decade.[15]

While studies have shown that individuals born in winter months are disproportionately likely to develop schizophrenia, Davis participated in a 2006 study that demonstrated that this disproportionality also exists in tropical regions, ruling out cold weather as the cause.[16]

Awards and recognition

  • Career Development Award, Veterans Administration
  • A.E. Bennett Award of the Society of Biological Psychiatry
  • American Psychiatric Association Award for Research in Psychiatry
  • Elected member, Institute of Medicine, National Academy of Science
  • President, American College of Neuropsychopharmacology[17]
  • 2009 George H. W. Bush Lifetime of Leadership Award[18]

Books

  • Alzheimer's Disease: Questions and Answers by Kenneth Davis and Kenneth L Davis and Paul S. Aisen and Deborah B. Marin, Softcover, Merit Pub Intl, ISBN 1-873413-36-X (1-873413-36-X)
  • Brain Acetylcholine and Neuropsychiatric Disease by Philip A. Berger and Kenneth L Davis, Hardcover, Plenum Press, ISBN 0-306-40157-6 (0-306-40157-6)
  • Neuropsychopharmacology: The Fifth Generation of Progress by American College of Neuropsychopharmacology and Joseph T. Coyle and Charles Nemeroff and Dennis Charney and Kenneth L Davis, Hardcover, Lippincott Williams & Wilkins, ISBN 0-7817-2837-1 (0-7817-2837-1)

References

  1. ^ A new rating scale for Alzheimer's disease, American Journal of Psychiatry
  2. ^ "Mt Sinai Hospital -- IRS Form 990 2017". Pro Publica Non Profit Explorer. Retrieved July 1, 2019. {{cite web}}: |archive-date= requires |archive-url= (help)
  3. ^ New York Times
  4. ^ "Board of Trustees – The Aspen Institute". The Aspen Institute. Retrieved 2017-05-16.
  5. ^ Institute, The Aspen. "Six Leaders Elected to Aspen Institute Board of Trustees". www.prnewswire.com. Retrieved 2017-05-16.
  6. ^ "Mt Sinai Hospital IRS Form 990, Return of Organization Exempt From Income Tax (2017)". Pro Publica Nonprofit Explorer. July 1, 2019. Retrieved July 1, 2019.
  7. ^ Bachai, Sabrina (2017-12-05). "Congress should massively ramp up funding for the NIH". TheHill. Retrieved 2018-06-06.
  8. ^ Fox, Michelle (2018-05-17). "'Outrageous' drug prices are a fair trade issue: Mt. Sinai CEO". CNBC. Retrieved 2018-06-06.
  9. ^ U.S. Food and Drug Administration
  10. ^ a b Science Magazine
  11. ^ Strong New Evidence Found of Inherited Alzheimer Risk, New York Times
  12. ^ The Journal of the American Medical Association
  13. ^ Myelin and oligodendrocyte abnormalities in schizophrenia, Cambridge Journals
  14. ^ Schizophrenia, Bipolar May Share Cause, WebMD.com
  15. ^ Science Watch
  16. ^ Seasonality effects on schizophrenic births in multiplex families in a tropical island
  17. ^ "Archived copy". Archived from the original on 2015-03-09. Retrieved 2015-04-06.{{cite web}}: CS1 maint: archived copy as title (link)
  18. ^ "Yale Bulldogs: Yale Athletic Department Hosts Blue Leadership Ball". Retrieved December 31, 2009.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Kenneth_L._Davis&oldid=994303465"